Firefly Neuroscience announced that its FDA-510(k) cleared Brain Network Analytics, BNA, biomarker discovery AI platform will be used to support Arrivo Bioventures’ Phase 1 exploratory study of its first-in-class SIRT6 activator, SP-624, in healthy volunteers and patients with major depressive disorder, MDD. The study, which has enrolled its first subject, is designed to evaluate the impact of the epigenetic mechanism of action of SP-624 on neurological pathways and assess changes in various cognitive domains. SP-624 is also currently being studied in a large Phase 2b study in patients diagnosed with MDD, with efficacy in females as the primary endpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIFF:
- Firefly Neuroscience files to sell 2.56M shares of common stock for holders
- Firefly Neuroscience collaborates with Takeda, Novartis
- Firefly Neuroscience enters partnership with Zeto
- Firefly Neuroscience appoints Stella Vnook to board of directors
- Firefly Neuroscience formed strategic partnership with NCD